deeptech Value proposition
[Automatic translation follows] Bringing solutions to patients with Rare Diseases
OrphanDev is the national network of expertise dedicated to rare diseases. Created in 2009, the OrphanDev network was awarded the F-CRIN label in 2021.
It is a unique public-private collaborative initiative that brings together healthcare professionals, researchers, entrepreneurs, manufacturers (biotech, medtech, pharmaceutical laboratories and their representatives, etc.), patients and patients' families, all mobilized to provide innovative solutions to patients with rare diseases. OrphanDev is coordinated by Professor Olivier Blin.
OrphanDev's action is structured around 3 axes:
• The operationalization of clinical research on rare diseases, in order to strengthen the attractiveness of research centers and facilitate the inclusion of French patients in international trials.
• The development of artificial intelligence for rare diseases in order to accelerate the collection, pooling and exploitation of data, to model the health pathway, to identify new pharmacological targets, to improve diagnosis or to encourage individualized medicine.
• The accessibility of treatments to allow patients to benefit from the latest therapeutic innovations.
* F-CRIN is a national infrastructure in clinical research. Labeled by the ANR as part of the Future Investment Program, supported by the Ministry of Health, its mission is to strengthen the performance of French clinical research and its attractiveness at the European and international level. A distributed infrastructure, it has 21 components, thematic networks of investigation and expertise, cutting-edge service platforms, of which OrphanDev is a part.
Rare Diseases, Orphan Drug Designation, Clinical Trials, Orphan Drugs, and Clinical trialOriginal language
Bring solutions to patients with Rare Diseases
OrphanDev est le réseau national d'expertise dédié aux maladies rares. Créé en 2009, le réseau OrphanDev est labellisé F-CRIN en 2021.
Il s’agit une initiative collaborative public-privé unique qui rassemble professionnels de santé, chercheurs, entrepreneurs, industriels (biotech, medtech, laboratoires pharmaceutiques et leurs représentants, etc.), patients et familles de patients, tous mobilisés pour apporter des solutions innovantes aux patients atteints de maladies rares. OrphanDev est coordonné par le Pr Olivier Blin.
L’action d’OrphanDev s’articule autour de 3 axes :
• L’opérationnalisation de la recherche clinique sur les maladies rares, afin de renforcer l’attractivité des centres de recherche et faciliter l’inclusion de patients français dans les essais internationaux.
• Le développement de l’intelligence artificielle au service des maladies rares afin d’accélérer le recueil, la mise en commun et l’exploitation des données, de modéliser le parcours de santé, d’identifier de nouvelles cibles pharmacologiques, d’améliorer le diagnostic ou encore d’encourager la médecine individualisée.
• L’accessibilité des traitements pour permettre aux patients de bénéficier des dernières innovations thérapeutiques.
* F-CRIN est une infrastructure d'envergure nationale en recherche clinique. Labélisée par l'ANR dans le cadre du Programme d'Investissements d'avenir, soutenue par le ministère de la Santé, elle a pour mission de renforcer la performance de la recherche clinique française et son attractivité au plan européen et international. Infrastructure distribuée, elle compte 21 composantes, réseaux thématiques d'investigation et d'expertises, plateformes de services de pointe, dont fait partie OrphanDev.
Maladies rares, Rare Diseases, Designation médicament orphelin, Essais cliniques, Orphan Drugs, and Clinical trial
- https://www.orphan-dev.org
- Website is disabled or domain is for sale
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 | Agence Régionale de Santé Grand Est | Other 4 Oct 2024 | | |
 France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | Other 4 Oct 2024 | | |
 Novartis Pharmaceutical, Pharmaceutical Manufacturing | Novartis Pharmaceutical, Pharmaceutical Manufacturing | Other 4 Oct 2024 | | |
 | ANSM Agence nationale de sécurité du médicament et des produits de santé | Other 6 Jul 2024 | | |
 SATT Sud-Est Research, National and local authorities, Research Services | SATT Sud-Est Research, National and local authorities, Research Services | Other 10 Jul 2024 | | |
 | Ministère de la Santé | Other 30 Nov 2023 | | |
 Illumina Biotechnology, Biotechnology Research | Illumina Biotechnology, Biotechnology Research | Other 30 Nov 2023 | | |
 Leem Startup accelerator & VC, Pharmaceutical Manufacturing | Leem Startup accelerator & VC, Pharmaceutical Manufacturing | Other 4 Oct 2024 | | |
 Alexion Pharmaceuticals, Inc. Pharmaceutical, Biotechnology, Biotechnology Research | Alexion Pharmaceuticals, Inc. Pharmaceutical, Biotechnology, Biotechnology Research | Other 18 Oct 2024 | | |
 Greater Paris University Hospitals - AP-HP Health, Hospitals and Health Care | Greater Paris University Hospitals - AP-HP Health, Hospitals and Health Care | Other 4 Oct 2024 | | |